What's new?

Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk

Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash   Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson   PARIS, France – June 11, 2020 - Sofinnova Partners, a leading European life sciences venture capital firm...

Neurotech S.A. initiates Phase I/II Clinical Study in Brain Cancer

 

Actelion is going public

 

Actelion and Genentech sign licensing agreement for tezosentan in the US

 

IWT and European Comission support confirm CropDesign's leading position

 

Kosan Biosciences Announces Publication Of Heterologous Expression Of Potential Anti-Cancer Agent, Epothilone, In Science

 

Kosan appoints vice President, Finance/CFO

Hayward CA. -Kosan Biosciences, Inc. announced today that Susan M. Kanaya has joined the company as Vice President, Finance and Chief Financial Officer.

Actelion Announces Recruitment of First Patients in its Phase III Clinical Development Program on Tezosentan in Acute Heart Failure

Allschwil. Actelion Ltd. today announced that it has begun its international Phase III clinical development program on tezosentan for intravenous use in patients with acute heart failure.

1 ... 177 178 179